Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2022 wishlist
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19
      • Explainer: A bold proposal at the WTO by India and South Africa
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
      • Explainer: COVID-19 vaccines - Recommendations for equitable access
      • Share the Tech - Save Lives
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • No Patents in a Pandemic
      • 20 years of Advocacy in Action
      • Share the Tech - Save Lives
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    MSF Access Missions Medicines Should Not be a Luxury
    Image link
    /1999-2019-20-years-advocacy-action
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Newsletters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    • Blog
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2022 wishlist
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19
      • Explainer: A bold proposal at the WTO by India and South Africa
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
      • Explainer: COVID-19 vaccines - Recommendations for equitable access
      • Share the Tech - Save Lives
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • No Patents in a Pandemic
      • 20 years of Advocacy in Action
      • Share the Tech - Save Lives
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    MSF Access Missions Medicines Should Not be a Luxury
    Image link
    /1999-2019-20-years-advocacy-action
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Newsletters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    • Blog
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!
Get involved
Share the Tech - Save Lives
Share the Tech

If mRNA vaccine technology from Moderna, BioNTech and Pfizer were shared, manufacturers in low- and middle-income countries could produce vaccines for global pandemic preparedness, as well as diseases of concern such as HIV, TB and malaria.

MSF Access Campaign

Read MAKING THE SWITCH, our NEW technical brief on optimal treatment for drug-resistant #tuberculosis, for the latest on:✅ Benefits for people with DR-TB✅ Costs of recommended regimens✅ Action needed to overcome barriers to effective treatment👉 ow.ly/hOZF50whNK2

06:32 - 20 Sep 2019
Navigate
  • About the Access Campaign
  • 1999-2019: 20 Years of Advocacy in Action
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access Campaign
Médecins Sans Frontières
Rue de Lausanne 78
P.O Box 1016
CH-1211 Geneva 1, Switzerland
Phone:+41 22 849 8484 Fax:+41 22 849 8404
E-mail: access(at)msf.org

Follow us on Twitter and Facebook
  • Twitter
  • Vimeo
  • Facebook
Medicines Shouldn't Be A Luxury